DOG Deutsche Ophthalmologische Gesellschaft
  English Site Suche:  
  107. DOG-Kongress Home

DOG-Kongressinformation

DOG-Kongress Bildergalerie

Grußworte
Organisation, Termine
Ablauf des Kongresses
Preise und Forschungsförderungen

Höhepunkte

Wissenschaftliches Programm
Feierliche Eröffnung
Schwerpunkte
Wissenschaftliches Programm
- Do, 24.09.09
- Fr, 25.09.09
- Sa, 26.09.09
- So, 27.09.09
- Posterausstellung
Symposien
Kurse
Firmenveranstaltungen
Satellitenprogramm

Hinweise, Informationen
Rahmenprogramm
Sponsoren, Industrie

Presseservice

Programm downloaden / drucken [PDF, 11 MB]

Vorprogramm downloaden / drucken [PDF, 3 MB]

DOG-Homepage
 

Abstract

DO.08.02

Whole-body Positron Emission Tomography/Computed tomography (PET/CT) imaging in the follow-up of metastatic uveal melanoma

Annemarie Klingenstein1, Alexander Haug2, Martin M. Nentwich1, Reinhold Tiling2, Ulrich C. Schaller1
1Augenklinik der Ludwig-Maximilians-Universität München, München; 2Klinik für Nuklearmedizin der Ludwig-Maximilians Universität München, München

Objective
The uveal melanoma is the most frequent primary intraocular tumor in adults. Metastatic disease has been reported in the follow-up of up to 50% of patients. Established oncological diagnostic modalities in tumor follow-up so far only dispose of limited sensitivity and specifity.
The diagnostic value of combined positron emission tomography (PET) / computer tomography (CT) in the follow-up of patients with metastatic uveal melanoma was assessed.
Methods
Nine patients with successfully treated uveal melanoma underwent combined PET/CT. The indication for PET/CT was heterogenous and reached from suspected metastatic choroidal melanoma in conventional imaging (n=2) to exclusion of further organ involvement before local therapy of liver metastases (n=3) and restaging after local or systemic therapy of metastases (n=4).
Results
PET/CT revealed vital metastases from uveal melanoma in all patients (n=9). 8 patients showed hepatic (89%), 5 patients osseous (56%), one patient pulmonary (11%), one patient adrenal (11%) and 3 patients lymphatic metastases (33%). 5 patients showed multiple organ involvement (56%). Additionally, PET/CT could rule out pulmonary metastatic involvement with suspicious intrapulmonary findings in CT and chest-X-ray in 2 patients. It could also confirm an equivocal intrahepatic finding in MRI as a vital metastasis.
Conclusions
Accurate whole-body-staging is of eminent importance both for the determination of adequate therapy (local versus systemic) and assessment of therapy response. In our retrospective study, PET/CT proved as a very sensitive and specific tool for the detection and localization of metastatic disease. In one single examination, it was able to assess both anatomic morphology as well as cell metabolism.

 
Zurück    
Seitenanfang